Genomic profiling assays was covered by Japanese national health insurance in June 2019, and cancer genome medicine has started. Prior to this, the Ministry of Health, Labor and Welfare designated facilities that can provide cancer genome medicine. The designated facilities are entrusted with the mission to test not only their own patients but also those of local hospitals. Therefore, cooperation among hospitals is necessary, and each hospital is devising its own unique approach. In this section, we will introduce the efforts of Tohoku University Hospital as a core hospital for cancer genome medicine in terms of inter-hospital collaboration.
|Number of pages||3|
|Journal||Gan to kagaku ryoho. Cancer & chemotherapy|
|Publication status||Published - 2022 Sept 1|
ASJC Scopus subject areas